FY2025 EPS Estimates for Amgen Reduced by Cantor Fitzgerald

Amgen Inc. (NASDAQ:AMGN) – Investment analysts at Cantor Fitzgerald dropped their FY2025 EPS estimates for shares of Amgen in a research note issued to investors on Thursday, October 9th. Cantor Fitzgerald analyst C. Gould now expects that the medical research company will earn $21.30 per share for the year, down from their previous estimate of $21.35. Cantor Fitzgerald has a “Neutral” rating and a $305.00 price target on the stock. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, beating the consensus estimate of $5.28 by $0.74. The business had revenue of $9.18 billion for the quarter, compared to the consensus estimate of $8.86 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS.

Other equities research analysts have also recently issued reports about the company. Citigroup raised their price target on Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a report on Wednesday, September 24th. Raymond James Financial initiated coverage on Amgen in a research report on Wednesday, September 3rd. They set a “market perform” rating for the company. Wall Street Zen cut Amgen from a “buy” rating to a “hold” rating in a report on Saturday. William Blair restated an “outperform” rating on shares of Amgen in a research note on Tuesday, June 24th. Finally, UBS Group reduced their price objective on shares of Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 6th. Eight analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Amgen currently has an average rating of “Hold” and an average target price of $309.42.

Amgen Stock Up 0.8%

AMGN opened at $292.40 on Monday. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. Amgen has a fifty-two week low of $253.30 and a fifty-two week high of $335.88. The firm’s fifty day moving average is $286.58 and its 200 day moving average is $287.33. The stock has a market cap of $157.42 billion, a price-to-earnings ratio of 23.91, a price-to-earnings-growth ratio of 2.52 and a beta of 0.49.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were given a dividend of $2.38 per share. The ex-dividend date was Friday, August 22nd. This represents a $9.52 annualized dividend and a yield of 3.3%. Amgen’s dividend payout ratio (DPR) is 77.84%.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the transaction, the senior vice president directly owned 7,209 shares of the company’s stock, valued at $2,141,000.91. This trade represents a 14.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.69% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in AMGN. Wealth Preservation Advisors LLC purchased a new position in shares of Amgen in the 1st quarter worth approximately $25,000. First Pacific Financial lifted its position in Amgen by 304.5% in the first quarter. First Pacific Financial now owns 89 shares of the medical research company’s stock worth $28,000 after buying an additional 67 shares during the last quarter. CBIZ Investment Advisory Services LLC boosted its stake in Amgen by 1,214.3% during the first quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock worth $29,000 after buying an additional 85 shares during the period. Legacy Investment Solutions LLC bought a new position in Amgen during the second quarter valued at $27,000. Finally, Activest Wealth Management raised its stake in shares of Amgen by 3,433.3% in the first quarter. Activest Wealth Management now owns 106 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 103 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.